PCSK9 Inhibitors for Homozygous Familial Hypercholesterolemia: Useful But Seldom Sufficient

Affiliations

Free article

Editorial

Gilbert R Thompson. J Am Coll Cardiol. 2020.

Free article

. 2020 Jul 14;76(2):143-145.

doi: 10.1016/j.jacc.2020.05.033.

¹ Faculty of Medicine, Hammersmith Hospital Campus, Imperial College London, London, United Kingdom. Electronic address: g.thompson@imperial.ac.uk.

No abstract available

Keywords: PCSK9 inhibitor; alirocumab; apheresis; evolocumab; homozygous FH; lomitapide.

Comment on

Efficacy and Safety of Alirocumab in Adults With Homozygous Familial Hypercholesterolemia: The ODYSSEY HoFH Trial.
Blom DJ, Harada-Shiba M, Rubba P, Gaudet D, Kastelein JJP, Charng MJ, Pordy R, Donahue S, Ali S, Dong Y, Khilla N, Banerjee P, Baccara-Dinet M, Rosenson RS. Blom DJ, et al. J Am Coll Cardiol. 2020 Jul 14;76(2):131-142. doi: 10.1016/j.jacc.2020.05.027. J Am Coll Cardiol. 2020. PMID: 32646561 Clinical Trial.